dc.creator | Papadaki M.A., Aggouraki D., Vetsika E.-K., Xenidis N., Kallergi G., Kotsakis A., Georgoulias V. | en |
dc.date.accessioned | 2023-01-31T09:42:01Z | |
dc.date.available | 2023-01-31T09:42:01Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.21873/ANTICANRES.14817 | |
dc.identifier.issn | 02507005 | |
dc.identifier.uri | http://hdl.handle.net/11615/77535 | |
dc.description.abstract | Background: To investigate the correlation between circulating tumor cells (CTCs) bearing cancer stem cell (CSC) and epithelial-to-mesenchymal (EMT) phenotypes and the different immunosuppressive cells in peripheral blood of patients with metastatic breast cancer (mBC). Materials and Methods: Blood was obtained from 38 pre-treated patients with mBC before a new line of treatment. CTC detection and characterization was performed by triple immunofluorescent staining, while Myeloid-derived Suppressor Cells (MDSCs) and T regulatory cells (Tregs) were analyzed by multi-flow cytometry. Results: CTCs were detected in 16 (42.1%) of patients. Based on the co-expression of ALDH1, TWIST and CK, CTCs revealed an important heterogeneity: CTCs with a CSC/partial-EMT, CSC/Epithelial-like, non-CSC/partial-EMT and non-CSC/Epithelial-like phenotype were detected in 7 (18.4%), 7 (18.4%), 1 (1.4%) and 9 (23.7%) of patients, respectively. Immunophenotyping of MDSCs identified 2 monocytic [M-MDSCs; CD14+CD15+CD11b+CD33+HLADR- Lin- (CD14+CD15+) and CD14+CD15-CD11b+CD33+HLA-DR-Lin- (CD14+CD15-)] and one granulocytic [GMDSCs; CD14-CD15+CD11b+CD33+HLA-DR-Lin- (CD14- CD15+)] subpopulations, expressing inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS), respectively. Patients with detectable CTCs had a higher frequency of Tregs (CD3+CD4+CD25high; p=0.022) whereas a positive correlation was found between CTC counts and the percentage of Tregs (p=0.005) and CD14+CD15+M-MDSCs (p=0.024). Patients with a partial-EMT phenotype had a higher frequency of CD14+CD15+M-MDSCs (p=0.023). Patients harboring the non-CSC/epithelial-like CTC subpopulation had an increased frequency of CD14-CD15+GMDSCs (p=0.020), along with decreased levels of CD3+CD4+CD25high FoxP3+Tregs (p=0.020). Conclusion: These findings provide evidence that CTCs in ER+/HER2- mBC patients may be under the control of the immune system and various immune escape mechanisms might be involved during the different stages of their biological evolution. © 2021 International Institute of Anticancer Research. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Anticancer Research | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100683779&doi=10.21873%2fANTICANRES.14817&partnerID=40&md5=d4f3dc1c6a8f68e1f22e6e0c6de38127 | |
dc.subject | aldehyde dehydrogenase isoenzyme 1 | en |
dc.subject | antineoplastic agent | en |
dc.subject | CD11b antigen | en |
dc.subject | CD14 antigen | en |
dc.subject | CD15 antigen | en |
dc.subject | CD3 antigen | en |
dc.subject | CD33 antigen | en |
dc.subject | CD4 antigen | en |
dc.subject | epidermal growth factor receptor 2 | en |
dc.subject | HLA DR antigen | en |
dc.subject | inducible nitric oxide synthase | en |
dc.subject | reactive oxygen metabolite | en |
dc.subject | transcription factor Twist | en |
dc.subject | Twist related protein 1 | en |
dc.subject | tumor marker | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | breast carcinoma | en |
dc.subject | cancer chemotherapy | en |
dc.subject | cancer hormone therapy | en |
dc.subject | CD25+ T lymphocyte | en |
dc.subject | CD3+ T lymphocyte | en |
dc.subject | CD4+ T lymphocyte | en |
dc.subject | cell heterogeneity | en |
dc.subject | cell subpopulation | en |
dc.subject | circulating tumor cell | en |
dc.subject | clinical article | en |
dc.subject | controlled study | en |
dc.subject | epithelial mesenchymal transition | en |
dc.subject | female | en |
dc.subject | flow cytometry | en |
dc.subject | fluorescence activated cell sorting | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | human epidermal growth factor receptor 2 negative breast cancer | en |
dc.subject | immunofluorescence assay | en |
dc.subject | immunophenotyping | en |
dc.subject | lobular carcinoma | en |
dc.subject | myeloid-derived suppressor cell | en |
dc.subject | priority journal | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | systemic therapy | en |
dc.subject | blood | en |
dc.subject | breast tumor | en |
dc.subject | cancer stem cell | en |
dc.subject | case control study | en |
dc.subject | comparative study | en |
dc.subject | immunology | en |
dc.subject | metabolism | en |
dc.subject | middle aged | en |
dc.subject | myeloid-derived suppressor cell | en |
dc.subject | pathology | en |
dc.subject | phenotype | en |
dc.subject | regulatory T lymphocyte | en |
dc.subject | tumor embolism | en |
dc.subject | tumor escape | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Biomarkers, Tumor | en |
dc.subject | Breast Neoplasms | en |
dc.subject | Case-Control Studies | en |
dc.subject | Epithelial-Mesenchymal Transition | en |
dc.subject | Female | en |
dc.subject | Flow Cytometry | en |
dc.subject | Humans | en |
dc.subject | Immunophenotyping | en |
dc.subject | Middle Aged | en |
dc.subject | Myeloid-Derived Suppressor Cells | en |
dc.subject | Neoplastic Cells, Circulating | en |
dc.subject | Neoplastic Stem Cells | en |
dc.subject | Phenotype | en |
dc.subject | T-Lymphocytes, Regulatory | en |
dc.subject | Tumor Escape | en |
dc.subject | International Institute of Anticancer Research | en |
dc.title | Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with mdscs and tregs in HER2-negative metastatic breast cancer patients | en |
dc.type | journalArticle | en |